针对中心型及超中心型肺部肿瘤的风险适应性立体定向消融放疗
该研究纳入2009至2016年137例不适合或拒绝手术的原发或复发肺癌患者,采用风险适应性分割(处方剂量40-60 Gy,3-8次)并优先保护危及器官的立体定向消融放疗(SABR)。中心型肿瘤60例、超中心型77例,中位随访36个月,全组中位总生存期(OS)46个月、无病生存期(DFS)33个月,1年和2年局部控制(LC)率分别为95%和81%,中心型与超中心型中位OS分别为57个月与37个月(HR 0.48,p=0.017),LC无差异,观察到4例3级和6例5级毒性(无4级)。
要点
- 全组中位OS 46个月、DFS 33个月,1年和2年LC率分别为95%和81%。
- 中心型与超中心型中位OS分别为57个月与37个月(HR 0.48,p=0.017),LC无差异。
- 观察到4例3级和6例5级毒性(无4级),3-5级毒性发生率为7.3%。
核心结论
- 中心型及超中心型肺部肿瘤的SABR可获得良好的OS、DFS和LC率,3-5级毒性发生率为7.3%。
- 在本队列中,中心型肿瘤预后优于超中心型肿瘤。
研究设计与样本
- 纳入拒绝手术或不适合手术的原发或复发肺癌患者,采用风险适应性分割SABR,处方剂量40-60 Gy,3-8次,并优先保护危及器官。
- 2009年至2016年共治疗137例患者,中位年龄75岁,中心型肿瘤60例,超中心型肿瘤77例,中位随访36个月。
主要发现
- 中位肿瘤大小2.5 cm(0.9-7),中位GTV 7.8 cm3(0.7-94.2),中位PTV 30.6 cm3(6.5-274.3)。
- 全组中位OS 46个月,中位DFS 33个月;1年和2年LC率分别为95%和81%。
- 中心型与超中心型中位OS分别为57个月与37个月(HR 0.48,p=0.017),LC在两者间无差异。
- 观察到4例3级和6例5级毒性,无4级毒性。
关键数值与推荐
- 中心型定义为肿瘤位于近端支气管树(PBT)周围2 cm区域内。
- 超中心型定义为PTV与PBT、食管、大血管和心包胸膜重叠。
- 处方剂量为40-60 Gy,分3-8次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SABR is a widely accepted treatment for early-stage lung cancer but there are safety concerns for central and ultra-central tumours. Herein we report our experience using risk-adapted fractionation (prescribed doses: 40-60 Gy in 3-8 fractions) with prioritization of dose to organs at risk. METHODS: Patient declining or unsuitable for surgery with primitive or recurrent lung cancer were included. Tumours inside a 2 cm area around proximal bronchial tree (PBT) were classified as central while tumours with PTV overlapping PBT, oesophagus, great vessels and pericardial pleura were classified as ultra-central. We assessed overall survival (OS), disease-free survival (DFS), local control (LC) and toxicities. RESULTS: From 2009 to 2016, 137 patients were treated (median age: 75 years), with 60 central and 77 ultra-central tumours. Median follow-up was 36 months. Median tumour size, GTV and PTV were 2.5 cm (0.9-7), 7.8 cm3 (0.7-94.2) and 30.6 cm3 (6.5-274.3), respectively. For the whole population, median OS and DFS were 46 months and 33 months. One- and 2-years LC rates were 95% and 81%. Median OS between central and ultra-central tumours was statistically different with 57 vs 37 months (HR 0.48, p = 0.017), but LC was not different among them. We observed 4 Grade 3 and 6 Grade 5 toxicities (no grade 4). CONCLUSIONS: SABR for central and ultra-central tumours is associated with good OS, DFS and LC rates, with 7.3% grade 3-5 toxicities. Central tumours had a better prognosis in our cohort.
引用
- Lenglet A, Campeau MP, Mathieu D, et al. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours. Radiother Oncol. 2019. PMID: 31005213. doi:10.1016/j.radonc.2019.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。